I respect your reasoning, but they won't have anything else to offer for 2 yrs (Lympro is a dud, Ovadx is Jan 2018 and MSPrecise is in limbo). In the mean time, no additional revenue generating tests other than what they have go bears.
T
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links